𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells

✍ Scribed by Jing Wan; Peter Sazani; Ryszard Kole

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
354 KB
Volume
124
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The oncogene HER2 is overexpressed in a variety of human tumors, providing a target for anti‐cancer molecular therapies. Here, we employed a 2′‐O‐methoxyethyl (MOE) splice switching oligonucleotide, SSO111, to induce skipping of exon 15 in HER2 pre‐mRNA, leading to significant downregulation of full‐length HER2 mRNA, and simultaneous upregulation of Δ15HER2 mRNA. SSO111 treatment of SK‐BR‐3 cells, which highly overexpress HER2, led to inhibition of cell proliferation and induction of apoptosis. The novel Δ15HER2 mRNA encodes a soluble, secreted form of the receptor. Treating SK‐BR‐3 cells with exogenous Δ15HER2 protein reduced membrane‐bound HER2 and decreased HER3 transphosphorylation. Δ15HER2 protein thus has similar activity to an autoinhibitory, natural splice variant of HER2, Herstatin, and to the breast cancer drug Herceptin. Both SSO111 and Δ15HER2 may be potential candidates for the development of novel HER2‐targeted cancer therapeutics. © 2008 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Genistein sensitizes inhibitory effect o
Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells
✍ Zhiming Mai; George L. Blackburn; Jin-Rong Zhou 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

## Abstract Although tamoxifen (TAM) is used for the front‐line treatment and prevention of estrogen receptor‐positive (ER+) breast tumors, nearly 40% of estrogen‐dependent breast tumors do not respond to TAM treatment. Moreover, the positive response is usually of short duration, and most tumors e